Amylin Pharmaceuticals Inc: Highlights
Financial data in U.S. dollars
| Financial Highlights |
|---|
| Sales |
816.77 Mil |
| Income |
-240.06 Mil |
| Net Profit Margin |
-29.39% |
| Return on Equity |
-52.93% |
| Debt/Equity Ratio |
1.66 |
|
| Revenue/Share |
5.85 |
| Earnings/Share |
-1.73 |
| Book Value/Share |
3.26 |
| Dividend Rate |
0.00 |
| Payout Ratio |
NA |
|
| Revenue - Quarterly Results (in Millions) |
|---|
| | FY (12/09) | FY (12/08) | FY (12/07) |
|---|
| 1st Qtr | 193.7 | 197.2 | 172.0 |
| 2nd Qtr | 209.4 | 222.0 | 197.0 |
| 3rd Qtr | 211.2 | 218.4 | 190.0 |
| 4th Qtr | NA | 202.5 | 222.0 |
| Total | 614.3 | 840.1 | 781.0 |
| Earnings Per Share - Quarterly Results |
|---|
| | FY (12/09) | FY (12/08) | FY (12/07) |
|---|
| 1st Qtr | -$0.34 | -$0.52 | -$0.38 |
| 2nd Qtr | -$0.44 | -$0.49 | -$0.34 |
| 3rd Qtr | -$0.19 | -$0.58 | -$0.30 |
| 4th Qtr | NA | -$0.76 | -$0.57 |
| Total | -$0.97 | -$2.35 | -$1.59 |
| Qtr. over Qtr. EPS Growth Rate |
| FY (12/09) | FY (12/08) | FY (12/07) |
|---|
| 1st Qtr | 55% | 9% | --- |
| 2nd Qtr | -29% | 6% | 11% |
| 3rd Qtr | 57% | -18% | 12% |
| 4th Qtr | NA | -31% | -90% |
| Yr. over Yr. EPS Growth Rate |
| FY (12/09) | FY (12/08) |
|---|
| 1st Qtr | 35% | -37% |
| 2nd Qtr | 10% | -44% |
| 3rd Qtr | 67% | -93% |
| 4th Qtr | NA | -33% |
advertisement
Recent News